Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nucleus Accumbens | 17 | 2021 | 417 | 4.040 |
Why?
|
| Astrocytes | 9 | 2022 | 270 | 3.300 |
Why?
|
| Glutamic Acid | 11 | 2021 | 332 | 2.920 |
Why?
|
| Cocaine | 12 | 2021 | 555 | 2.420 |
Why?
|
| Drug-Seeking Behavior | 16 | 2021 | 213 | 2.150 |
Why?
|
| Synapses | 11 | 2023 | 222 | 2.030 |
Why?
|
| Cues | 13 | 2021 | 654 | 1.410 |
Why?
|
| Methamphetamine | 5 | 2021 | 132 | 1.370 |
Why?
|
| Neuronal Plasticity | 11 | 2022 | 274 | 1.270 |
Why?
|
| Neurons | 8 | 2022 | 881 | 1.110 |
Why?
|
| Cocaine-Related Disorders | 8 | 2020 | 504 | 0.950 |
Why?
|
| Self Administration | 16 | 2021 | 419 | 0.880 |
Why?
|
| Dopamine Uptake Inhibitors | 5 | 2017 | 152 | 0.830 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2021 | 2083 | 0.800 |
Why?
|
| Behavior, Addictive | 4 | 2021 | 317 | 0.790 |
Why?
|
| Animals | 37 | 2023 | 20881 | 0.770 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2017 | 92 | 0.770 |
Why?
|
| Substance-Related Disorders | 5 | 2021 | 1242 | 0.760 |
Why?
|
| Extinction, Psychological | 7 | 2021 | 240 | 0.750 |
Why?
|
| Limbic System | 2 | 2020 | 106 | 0.730 |
Why?
|
| Rats | 21 | 2021 | 5300 | 0.720 |
Why?
|
| Microglia | 2 | 2021 | 143 | 0.700 |
Why?
|
| Central Nervous System Stimulants | 3 | 2018 | 221 | 0.690 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 455 | 0.620 |
Why?
|
| Nitric Oxide | 1 | 2020 | 382 | 0.600 |
Why?
|
| Synaptic Transmission | 6 | 2022 | 236 | 0.600 |
Why?
|
| Homeostasis | 2 | 2016 | 291 | 0.590 |
Why?
|
| Mental Disorders | 1 | 2022 | 659 | 0.550 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 179 | 0.540 |
Why?
|
| Receptors, Nicotinic | 3 | 2014 | 41 | 0.520 |
Why?
|
| Long-Term Synaptic Depression | 1 | 2015 | 32 | 0.490 |
Why?
|
| Ethanol | 1 | 2020 | 893 | 0.460 |
Why?
|
| Heroin | 3 | 2020 | 49 | 0.450 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 167 | 0.440 |
Why?
|
| Epigenomics | 1 | 2013 | 29 | 0.430 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 266 | 0.430 |
Why?
|
| Conditioning, Operant | 2 | 2014 | 241 | 0.400 |
Why?
|
| Repressor Proteins | 1 | 2012 | 183 | 0.390 |
Why?
|
| Dopaminergic Neurons | 3 | 2020 | 46 | 0.360 |
Why?
|
| Brain | 5 | 2021 | 2176 | 0.360 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 307 | 0.350 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 3 | 2014 | 26 | 0.350 |
Why?
|
| Phenotype | 1 | 2013 | 947 | 0.340 |
Why?
|
| Recurrence | 8 | 2020 | 948 | 0.320 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 700 | 0.320 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 1293 | 0.290 |
Why?
|
| Male | 20 | 2021 | 37321 | 0.290 |
Why?
|
| Perirhinal Cortex | 2 | 2018 | 5 | 0.290 |
Why?
|
| Calcium Channels, N-Type | 2 | 2017 | 7 | 0.280 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 3 | 2017 | 51 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 615 | 0.270 |
Why?
|
| Memory Disorders | 2 | 2018 | 111 | 0.260 |
Why?
|
| Nicotine | 2 | 2021 | 350 | 0.250 |
Why?
|
| Sucrose | 3 | 2022 | 58 | 0.240 |
Why?
|
| Amphetamine-Related Disorders | 2 | 2015 | 92 | 0.240 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2020 | 435 | 0.230 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2015 | 75 | 0.230 |
Why?
|
| Transcription Factors | 1 | 2008 | 753 | 0.230 |
Why?
|
| Anhedonia | 1 | 2023 | 15 | 0.220 |
Why?
|
| Rats, Long-Evans | 2 | 2020 | 203 | 0.220 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 58 | 0.210 |
Why?
|
| Parvalbumins | 1 | 2022 | 29 | 0.210 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2021 | 5 | 0.200 |
Why?
|
| Mice, Transgenic | 4 | 2020 | 1033 | 0.200 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 640 | 0.190 |
Why?
|
| Neuroimmunomodulation | 1 | 2021 | 16 | 0.190 |
Why?
|
| Neurogenesis | 1 | 2021 | 32 | 0.190 |
Why?
|
| Dendritic Spines | 3 | 2020 | 76 | 0.190 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2020 | 20 | 0.180 |
Why?
|
| Signal Transduction | 5 | 2021 | 2689 | 0.180 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2020 | 16 | 0.180 |
Why?
|
| Humans | 12 | 2023 | 68618 | 0.180 |
Why?
|
| Integrin beta3 | 1 | 2020 | 35 | 0.180 |
Why?
|
| Interneurons | 2 | 2021 | 70 | 0.180 |
Why?
|
| Immunoprecipitation | 2 | 2012 | 132 | 0.180 |
Why?
|
| Haploinsufficiency | 1 | 2020 | 14 | 0.180 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2020 | 87 | 0.180 |
Why?
|
| Calcium-Binding Proteins | 1 | 2020 | 114 | 0.180 |
Why?
|
| Microfilament Proteins | 1 | 2020 | 102 | 0.170 |
Why?
|
| Electrodes, Implanted | 1 | 2020 | 98 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 498 | 0.170 |
Why?
|
| Mice | 8 | 2023 | 8474 | 0.160 |
Why?
|
| Behavior, Animal | 2 | 2018 | 470 | 0.160 |
Why?
|
| Ceftriaxone | 2 | 2015 | 32 | 0.160 |
Why?
|
| Genetic Techniques | 1 | 2018 | 32 | 0.160 |
Why?
|
| Ventral Tegmental Area | 1 | 2018 | 74 | 0.150 |
Why?
|
| Cannabidiol | 1 | 2018 | 31 | 0.150 |
Why?
|
| Dronabinol | 1 | 2018 | 84 | 0.150 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2017 | 35 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 2550 | 0.140 |
Why?
|
| Vesicular Glutamate Transport Proteins | 1 | 2016 | 2 | 0.140 |
Why?
|
| Receptors, Ionotropic Glutamate | 1 | 2016 | 2 | 0.140 |
Why?
|
| Synapsins | 1 | 2015 | 11 | 0.130 |
Why?
|
| Animals, Genetically Modified | 1 | 2015 | 63 | 0.130 |
Why?
|
| Aspartic Acid | 2 | 2014 | 65 | 0.130 |
Why?
|
| Cell Count | 1 | 2015 | 248 | 0.130 |
Why?
|
| SNARE Proteins | 1 | 2015 | 5 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 170 | 0.130 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2015 | 20 | 0.130 |
Why?
|
| Dietary Sucrose | 1 | 2015 | 18 | 0.130 |
Why?
|
| Cycloserine | 1 | 2015 | 30 | 0.120 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 62 | 0.120 |
Why?
|
| Clozapine | 1 | 2015 | 46 | 0.120 |
Why?
|
| Exploratory Behavior | 1 | 2015 | 79 | 0.120 |
Why?
|
| Phenols | 1 | 2015 | 73 | 0.120 |
Why?
|
| Central Nervous System Agents | 1 | 2015 | 37 | 0.120 |
Why?
|
| Reward | 3 | 2022 | 201 | 0.120 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 52 | 0.120 |
Why?
|
| Piperidines | 1 | 2015 | 123 | 0.120 |
Why?
|
| Ion Channels | 1 | 2014 | 72 | 0.120 |
Why?
|
| Amino Acid Transport Systems, Acidic | 1 | 2014 | 2 | 0.120 |
Why?
|
| Substantia Nigra | 1 | 2014 | 102 | 0.120 |
Why?
|
| Nerve Degeneration | 1 | 2014 | 134 | 0.120 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2014 | 13 | 0.120 |
Why?
|
| Heroin Dependence | 1 | 2014 | 23 | 0.120 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2014 | 145 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 160 | 0.110 |
Why?
|
| Globus Pallidus | 1 | 2014 | 64 | 0.110 |
Why?
|
| Receptors, Opioid, mu | 1 | 2014 | 70 | 0.110 |
Why?
|
| Free Radical Scavengers | 1 | 2014 | 112 | 0.110 |
Why?
|
| Genetic Therapy | 1 | 2015 | 291 | 0.110 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2012 | 30 | 0.110 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 35 | 0.100 |
Why?
|
| Ubiquitination | 1 | 2012 | 85 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2012 | 155 | 0.100 |
Why?
|
| Embryo, Mammalian | 1 | 2012 | 176 | 0.100 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2014 | 208 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 493 | 0.100 |
Why?
|
| Cell Death | 1 | 2012 | 329 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2012 | 244 | 0.100 |
Why?
|
| Acetylcysteine | 1 | 2014 | 296 | 0.090 |
Why?
|
| Transfection | 1 | 2012 | 782 | 0.090 |
Why?
|
| Multigene Family | 1 | 2010 | 93 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1040 | 0.090 |
Why?
|
| Rats, Transgenic | 2 | 2020 | 24 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2014 | 447 | 0.090 |
Why?
|
| Protein Binding | 1 | 2012 | 1027 | 0.080 |
Why?
|
| Adolescent | 1 | 2022 | 8912 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2023 | 2791 | 0.080 |
Why?
|
| Aging | 1 | 2014 | 911 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 290 | 0.080 |
Why?
|
| Blotting, Northern | 1 | 2008 | 189 | 0.080 |
Why?
|
| Mice, 129 Strain | 2 | 2017 | 44 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 492 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 320 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 786 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2020 | 791 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 562 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2008 | 954 | 0.070 |
Why?
|
| Tobacco Use Disorder | 1 | 2010 | 432 | 0.060 |
Why?
|
| Stress, Psychological | 2 | 2023 | 824 | 0.060 |
Why?
|
| Cell Line | 1 | 2008 | 1752 | 0.060 |
Why?
|
| Social Behavior | 1 | 2023 | 164 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 1173 | 0.050 |
Why?
|
| Cholinergic Agents | 1 | 2021 | 12 | 0.050 |
Why?
|
| MEF2 Transcription Factors | 1 | 2020 | 36 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2020 | 223 | 0.040 |
Why?
|
| Prosencephalon | 1 | 2018 | 38 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2019 | 108 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 196 | 0.040 |
Why?
|
| Female | 3 | 2021 | 38074 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 929 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 2018 | 231 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2017 | 59 | 0.040 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2017 | 128 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 943 | 0.030 |
Why?
|
| Motor Activity | 1 | 2018 | 621 | 0.030 |
Why?
|
| Subthalamic Nucleus | 1 | 2014 | 16 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 56 | 0.030 |
Why?
|
| Mammals | 1 | 2014 | 47 | 0.030 |
Why?
|
| Morpholinos | 1 | 2014 | 8 | 0.030 |
Why?
|
| Heterozygote | 1 | 2014 | 174 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 122 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 167 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 204 | 0.030 |
Why?
|
| Piperazines | 1 | 2015 | 206 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2014 | 87 | 0.030 |
Why?
|
| Dopamine | 1 | 2016 | 474 | 0.030 |
Why?
|
| Potassium | 1 | 2014 | 168 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 317 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 765 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1745 | 0.030 |
Why?
|
| Long-Term Potentiation | 1 | 2013 | 53 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 291 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2014 | 447 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 442 | 0.030 |
Why?
|